Navigation Links
Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave®
Date:9/20/2011

forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release and the conference call due to the risk and uncertainties inherent in Orexigen's business, including, without limitation: Orexigen's ability to maintain and raise sufficient capital to fund the CVOT and maintain its other operations; the uncertainty of the FDA approval process, including requirements for additional clinical and non-clinical studies or other commitments prior to the submission and approval of an NDA for Contrave; Orexigen's ability to demonstrate that the risk of major adverse CV events in overweight and obese subjects treated with Contrave does not adversely affect the product candidate's benefit-risk profile; the potential for FDA's planned 2012 public advisory committee meeting on obesity drug development to result in additional NDA approval requirements for Contrave as well as post-approval commitments; Orexigen's dependence on Takeda Pharmaceuticals for aspects of the development and commercialization of Contrave; reliance on third parties to supply Contrave and assist with the development of Contrave and the regulatory submissions related thereto; the potential for adverse safety findings relating to Contrave; intense competition in the obesity marketplace and the potential for new products to emerge that provide different or better therapeutic alternatives for obesity and weight loss compared to Contrave; and other risks described in the Company's filings with the Securities and Exchange Commission (SEC). You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in Orexig
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Orexigen® Therapeutics Reports Second Quarter Ended June 30, 2011 Financial Results
2. Orexigen® Therapeutics Provides a Regulatory Update on Contrave® NDA
3. Orexigen® Therapeutics Reports First Quarter Ended March 31, 2011 Financial Results
4. Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results
5. Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
6. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
7. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
8. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
9. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
10. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
11. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), ... that it acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... The terms of the acquisition were not disclosed. ... company providing a wide range of sleep, mobility, and respiratory ...
(Date:1/14/2014)... NuAire , a manufacturer of ergonomically designed laboratory equipment ... of Japan to sell and service the ... NuAire will utilize its network of sales professionals throughout ... to offer assistance in application use, product benefits and features, options ...
(Date:1/14/2014)... 14, 2014 Equashield ( http://www.equashield.com ... drugs, today announced that it has achieved 60% ...   Equashield,s closed systems reduce the ... and other medical professionals who prepare and administer ...
Breaking Medicine Technology:Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Equashield's Sales Grow by 60% in 2013 2
(Date:4/17/2014)... Diego School of Medicine report that older women, plucky ... loss are more likely to be compassionate toward strangers ... in this month,s issue of the International Journal ... associated with better health and well-being as we age, ... the outcomes of individuals whose deficits in compassion put ...
(Date:4/17/2014)... Jon McCullers, MD, was recently invited to submit ... Nature Reviews Microbiology , one of the world,s ... infectious disease specialist, and chair of the Department ... Science Center, analyzed the epidemiology and microbiology of ... as well as more recent 2009 novel H1N1 ...
(Date:4/17/2014)... (April 17, 2014) Doctors who treat patients ... lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. ... the disease and help relieve shortness of breath. ... and sirolimus can cause potentially fatal complications following ... Dr. Daniel Dilling, medical director of Loyola University ...
(Date:4/17/2014)... 17, 2014-- Colic affects about one in five infants ... pediatric visits during the first several months after birth. ... was showing promise; however, the April 1, 2014 issue ... Valerie) reported on a study, "Probiotics and Infant Colic," ... reuteri for infant colic did not reduce ...
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit ... issues, published a comprehensive review today examining the current ... virus. The review calls for improved global surveillance strategies ... the recent outbreak of Ebola in West Africa that ... countries of Guinea and Liberia. According to the ...
Breaking Medicine News(10 mins):Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3
... Wrigley told the jurors that Dru Sjodin, 22, struggled for ... Rodriguez Jr. was the man responsible for her death.// ... has pleaded not guilty to a charge of abduction resulting ... of North Dakota. According to prosecutors, death penalty will be ...
... are hairier than others may have been discovered, according to ... embryonic skin cells will form into hair follicles, deciding the ... the University of Manchester. ,This study on mice ... -- a range of conditions in which skin cells fail ...
... be wary of the so-called stem cell wonder cures that ... tested.// ,The health experts had yesterday in a ... a world leader in stem cell research, but cautioned that ... cosmetic skin treatment were yet to be proven, and could ...
... from Johns Hopkins and made available on the World Wide ... to cilia operations in the body. // ,The researchers ... structures on the surface of cells called cilia as such ... 'orphaned diseases' all have links associated with the tiny, hair-like ...
... Paisley and the Raigmore in Inverness do not maintain hygiene ... Scotland. ,The study categorized hospitals by traffic light ... the set standards, amber for hospitals in the 70% and ... ERI, the rate was 84.1%, while Raigmore scored 83.1% and ...
... Institute of Virology in Pune declared Tuesday there is no ... from here in south Gujarat.// ,Additional director of ... Surat city, and not even a single sample contained Hantavirus." ... not yet clarified why two persons had died last week. ...
Cached Medicine News:Health News:The fate of an accused in a murder case to be decided 2Health News:Scientists In UK Issue A Caution Over Untested Stem Cell Treatments 2Health News:John Hopkins Develops An Online Tool To Help In Research Of Certain Rare Diseases 2Health News:John Hopkins Develops An Online Tool To Help In Research Of Certain Rare Diseases 3
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Medicine Products: